Details of the Drug Combination

General Information of Drug Combination (ID: DCGSYTI)

Drug Combination Name
BIO-300 Ixabepilone
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Ixabepilone   DM2OZ3G
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: HCC-2998
Zero Interaction Potency (ZIP) Score: 4.18
Bliss Independence Score: 4.11
Loewe Additivity Score: 5.78
LHighest Single Agent (HSA) Score: 6.86

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Ixabepilone
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [4]
Breast carcinoma N.A. Approved [5]
Ixabepilone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Stablizer [6]
------------------------------------------------------------------------------------
Ixabepilone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
------------------------------------------------------------------------------------
Ixabepilone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [8]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Astrocytoma DCQ87D0 SNB-19 Investigative [9]
Clear cell renal cell carcinoma DCSNOJB 786-0 Investigative [9]
Glioma DC5GNW3 SF-268 Investigative [9]
Renal cell carcinoma DC18Y85 SN12C Investigative [9]
Invasive ductal carcinoma DCDN1VU BT-549 Investigative [10]
Adenocarcinoma DCL1PJS NCIH23 Investigative [1]
Amelanotic melanoma DCE8X2P M14 Investigative [1]
Lung adenocarcinoma DC77HVF HOP-62 Investigative [1]
Malignant melanoma DCRAYZY UACC62 Investigative [1]
Non-small cell lung carcinoma DCRSA7X HOP-92 Investigative [1]
Pleural epithelioid mesothelioma DCKN3I1 NCI-H226 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6824).
5 Ixabepilone FDA Label
6 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
7 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
8 The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.
9 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
10 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.